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Purpose: The purpose of this study was to examine why Norway has the highest rate of 
mortality due to cutaneous melanoma (CM) in Europe. The Norwegian Malignant Melanoma 
Registry (NMMR) enables the study of clinical and histopathological characteristics of patients 
who die due to CM.
Patients and methods: The NMMR and the Norwegian Cause of Death Registry provided 
data on the clinical and histopathological factors as well as the date and cause of death, through 
June 2015 for all first invasive CMs diagnosed in 2008–2012 (n=8087). Cox regression was 
used to estimate associations between clinical and pathological factors and CM-specific death. 
Multiple imputation was used to handle missing data.
Results: The CMs were equally distributed between men (49.9%) and women (50.1%), and the 
median follow-up was 4.0 years (range: 0.08–7.5 years). Trunk was the most common anatomic 
site (48%), superficial spreading melanoma was the dominant melanoma subtype (68.2%), 
median Breslow thickness was 1.0 mm, ulceration was present in 23% of CMs, and 91.8% of 
cases were in a local clinical stage at diagnosis. Compared to women, men were diagnosed at 
a higher age, with thicker and more-often-ulcerated tumor, and more often were in advanced 
clinical stages. During follow-up, 1015 patients died due to CM, representing 52.8% of all deaths. 
The nodular subtype made up the dominant proportion of fatal CM cases (55.3% in women, 
64.6% in men). Sex, age, anatomic site (trunk), T-stage, ulceration, clinical stage, and having a 
second primary CM were associated with increased risk of CM-specific death.
Conclusion: Our data suggest that the high rate of mortality due to CM observed in Norway is 
attributable to the more advanced stage of the disease at diagnosis. Most high-risk cases occurred 
in male patients ≥70 years of age. Efforts to improve awareness and secondary prevention of 
CM, including warning signs of all melanoma subtypes, are required urgently and should be 
targeted toward men in particular.
Keywords: cutaneous melanoma, mortality, prognostic factors, diagnostic delay, epidemiology
Plain language summary
We were curious why Norway has the highest rate of mortality due to cutaneous melanoma (CM) 
in Europe. Data from the Norwegian Malignant Melanoma Registry (NMMR) enabled us to 
study patient and tumor characteristics among Norwegian patients, their relations to melanoma-
specific death, and compare our results with those from other countries. We included all patients 
diagnosed with their first CM in 2008–2012 (n=8087) and linked information on the date and 
cause of death. We found that trunk was the most common tumor site, superficial spreading 
melanoma (SSM) was the dominant subtype, median tumor thickness was 1.0 mm, about 20% 
of the tumors were ulcerated, and about 10% of patients had metastases at diagnosis. Compared 
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to women, men had thicker tumors and more advanced disease at 
diagnosis. During follow-up, 1015 patients died from melanoma. 
Factors that increased the risk of death were male sex, age ≥70 years, 
tumor site at the trunk, tumor thickness >1 mm, ulceration, metasta-
ses, and having a second tumor. Compared to other countries’ data, 
Norwegian patients have more advanced disease at diagnosis, which 
can explain our high mortality rate. Our results underline the need 
for improved public awareness, especially in men.
Introduction
The incidence of and mortality rates due to cutaneous mela-
noma (CM) in the Scandinavian countries are among the 
highest in Europe.1 In Norway, CM is the cancer with the 
steepest increase in incidence after 2000, with an annual 
increase of ~3.5%, and is now the fifth and fourth most fre-
quent cancer in men and women, respectively (all ages).2 The 
age-adjusted rate of mortality due to CM has also increased 
in both sexes, with the highest rate observed in men.2 In 
2012, the rate of mortality due to CM in Norway was 3.5 per 
100,000 (world standard population), which is ranked third 
worldwide and the highest in Europe (http://globocan.iarc.
fr/Pages/bar_sex_site_sel.aspx), although several European 
countries have higher or comparable incidence.
Tumor thickness (Breslow), ulceration, and presence of 
regional or distant metastasis at diagnosis are the most impor-
tant prognostic factors in CM.3–5 In the Nordic countries, most 
cases are diagnosed in an early stage of the disease, and in 
the period 1999–2003, the 5-year relative survival after CM 
was ~80% in men and 90% in women.6 In Sweden, increas-
ing CM incidence has been accompanied by a decrease in 
tumor thickness and improvement in survival in men.7 In 
Denmark and Norway, the largest increase in incidence has 
occurred for local-stage tumors.8,9 In Northwestern Euro-
pean countries, USA, and Australia, increasing incidence of 
CM is accompanied by a stable rate of mortality,10 raising 
the question whether the increase in incidence represents a 
true increase in risk or whether it is due to better detection, 
higher awareness, and potentially overdiagnosis of CM.11 
In Norway, however, the high and increasing mortality rate 
raises the question whether the CM diagnoses are delayed, 
particularly in men.
The NMMR was established in 2008 and now provides 
the opportunity to study clinical and histopathological 
characteristics of all primary invasive CM cases, diagnosed 
in 2008–2012, and the association of these characteristics 
with CM-specific death. Furthermore, we aimed to discuss 
the findings in relation to results reported from comparable 
countries and gain new knowledge to help target secondary 
prevention in the Norwegian population.
Patients and methods
Patients
The Cancer Registry of Norway (CRN) has recorded 
all cancer diagnoses nationwide since 1953. Mandatory 
reporting from independent sources ensures completeness 
and high-quality data.12 After 2000, >99% of all CM cases 
are morphologically verified.2,12 In 2008, the NMMR was 
established under the CRN, registering additional clinical 
and histopathological information related to each CM case.
In total, 8120 patients with a first primary invasive CM 
diagnosis in the period 2008–2012 were identified and 
included in the study. Sex, age at diagnosis, region of resi-
dence, anatomic site, melanoma subtype, Breslow thickness, 
T-stage, Clark level, presence of ulceration, clinical stage at 
diagnosis, and information on second primary CM during 
the study period were obtained from the NMMR.
Information on death and emigration was obtained by 
linkage to the Causes of Death Registry and the National 
Population Registry. The end of follow-up was on June 30, 
2015. The cause of death is set by the doctor, and reporting 
to the Causes of Death Registry is mandatory by law (since 
January 1, 1951). The 10th edition of the World Health Orga-
nization’s International Classification of Diseases is used. 
The unique 11-digit personal identification number system, 
implemented in Norway in 1964, secures the linkages. In all, 
33 (0.4%) cases were lost to follow-up, leaving 8087 cases 
for analyses.
All data were de-identified before analyses. Reporting 
from cancer-specific registries, with de-identified data, is 
regulated by the Norwegian law on health registries, needing 
no further ethical approval.
Clinical and histopathological variables
Based on age at diagnosis, the CM cases were divided into 
age groups (<50, 50–69, and ≥70 years). Codes for residen-
tial municipality at the time of diagnosis were categorized 
in accordance with the Norwegian Regional Health Author-
ity regions (South-Eastern, Western, Central, and Northern 
Norway Regional Health Authorities). As an indicator of 
dermatologist availability, residential codes were categorized 
as urban and rural areas.
The anatomic site of the primary tumor was classified 
according to the International Classification of Diseases for 
Oncology, Third Edition (ICDO-3)13 and categorized as head/
neck (190.0), trunk (190.1/190.7), upper extremity (190.2), 
lower extremity (190.3/190.4), and other (190.5/190.6/190.8). 
Cases without information on the anatomic site (190.9) were 
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High mortality due to cutaneous melanoma in Norway
Melanoma subtype is registered according to the fol-
lowing ICDO-3 codes:13 SSM (M87433), nodular mela-
noma (NM; M87213), lentigo maligna melanoma (LMM; 
M87423), acral lentiginous melanoma (ALM; M87443), 
melanoma unspecified (M87203), and other (M87453/
M87803/M87613). For 2126 cases, information on subtype 
was not given.
The Norwegian guidelines for the period 2008–2015 
advised reporting of Breslow thickness in millimeters to 1 
decimal point.14 Breslow thickness was categorized as the 
following T-stages: T1 (≤1.0 mm), T2 (1.01–2.0 mm), T3 
(2.01–4.0 mm), and T4 (>4.0 mm). Cases without infor-
mation on Breslow thickness (n=857) were categorized as 
unspecified.
Information on the Clark level (I–V) and ulceration (pres-
ent, not present) was used as registered in the NMMR. For a 
large proportion of cases (n=3638), information on ulceration 
was not specified. The CRN coding and classification system 
follows international standards,12 with some modifications 
for stage as described in the CRN annual report;2 based on 
information on clinical and histopathological notifications for 
each CM case, metastasis is coded by trained medical coders 
according to strict rules and local coding practice at the CRN. 
Clinical stage at diagnosis was categorized as follows: local 
disease (no metastases), regional metastasis (metastases in 
regional lymph nodes, satellites, and in-transit metastases), 
and distant metastasis (organ metastases and nonregional 
lymph node metastases). Cases without information about 
metastasis (n=1116) were categorized as unspecified.
Criteria for a new primary CM during the study period 
(0, 1, or >1) were different melanoma subtype, different 
anatomic site, or date of diagnosis at least 4 months after 
the first CM diagnosis.
Statistical analysis
Descriptive data are presented as frequencies (%) and medi-
ans (ranges). Differences between men and women were 
tested by the Mann–Whitney test for continuous variables 
and the chi-square test for categorical variables.
The CM cases were followed from the date of diagnosis 
until death, emigration, or end of follow-up (June 30, 2015), 
whichever occurred first. The traditional Kaplan–Meier 
estimator overestimates cumulative incidence in the pres-
ence of competing risk due to the incorrect assumption of 
non-informative censoring;15–17 thus, cumulative incidence of 
CM-specific death and that of death from other causes were 
estimated by a nonparametric method, taking competing 
events into account.15
Cox regression, with the time since date of CM diagnosis 
as the time scale, was used to study the association between 
the clinical and histopathological variables and CM-specific 
death. Results are presented as hazard ratios (HRs) with 95% 
confidence intervals (CIs). The melanoma subtype ALM was 
included in the “other” category due to low numbers, and 
the Clark level was not included due to the high correlation 
with T-stage. The incidence of a new primary CM during 
the study period was modeled as a time-dependent covari-
ate. Interaction between sex and age has previously been 
reported18 and was, thus, evaluated by a likelihood ratio test 
(with age dichotomized as <70/≥70 in complete-case data).
We imputed missing data (anatomic site, melanoma 
subtype, Breslow thickness, ulceration, and clinical stage) 
using multiple imputation with chained equations.19 A 
combined result was set after running the imputation model 
30 times.19 In addition, analyses were conducted based on 
complete-case data.
All statistical analyses were performed using Stata 14 
(StatCorp LP, College Station, TX, USA).
Results
Table 1 shows the characteristics of the total 8087 CM cases, 
in total and stratified by sex; the cases comprised 50.1% 
women and 49.9% men. The mean age at diagnosis was 
64 years, and men were older (65 years) than the women 
(62 years). The majority of the CM cases (61.2%) resided 
in areas under the South-Eastern Norway Regional Health 
Authority, and both sexes were similarly distributed in the 
regions.
The distribution of CM with regard to the anatomic site 
was different for men and women (Table 1) and varied by age 
(Figure 1). For both sexes, trunk was the most common loca-
tion (48.0%), but it was more common in men (60.4%) than 
in women (35.8%); women had more leg tumors (34.0% vs 
13.0%, respectively). Head/neck tumors were most frequent 
in patients ≥70 years of age in both sexes (Figure 1).
The dominant melanoma subtype was SSM (70.6% in 
women and 65.8% in men), followed by NM (22.8% in 
women and 28.6% in men; Table 1). The proportion of NM 
was highest in men for all anatomic sites (data not shown), 
with increasing proportion by age in both sexes (34.7% being 
NM in patients ≥70 years; Figure 1).
Median Breslow thickness was 1.0 mm in women and 
1.1 mm in men (Table 1). SSM tumors were thinner (median 
0.8 mm) than NM tumors (median 3.0 mm; data not shown). 
Men had thicker and more-invasive tumors than women. In 
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Table 1 Characteristics of the 8087 CM cases (2008–2012), total and stratified by sex
Characteristics Total Women Men P-value*
n (%) 8087 (100) 4052 (50.1) 4035 (49.9)  
Age (years), median (range) 64 (2–98) 62 (2–98) 65 (14–98) <0.001
Age group, n (%) <0.001
<50 years 1813 (22.4) 1093 (27.0) 720 (17.8)
50–69 years 3417 (42.2) 1622 (40.0) 1795 (44.4)
≥70 years 2857 (35.4) 1337 (33.0) 1520 (37.6)
Regional Health Authority, n (%) 0.230
South-Eastern 4957 (61.2) 2473 (61.0) 2484 (61.6)
Western 1728 (21.4) 872 (21.6) 856 (21.2)
Central 981 (12.2) 512 (12.6) 469 (11.6)
Northern 421 (5.2) 195 (4.8) 226 (5.6)
Urban–rural area, n (%) 0.451
Urban 3846 (47.6) 1944 (48.0) 1902 (47.2)
Rural 4241 (52.4) 2108 (52.0) 2133 (52.8)
Anatomic site, n (%) <0.001
Trunk 3656 (48.0) 1368 (35.8) 2288 (60.4)
Head/neck 1072 (14.0) 497 (13.0) 575 (15.2)
Arm 1055 (13.8) 640 (16.8) 415 (11.0)
Leg 1791 (23.6) 1303 (34.0) 488 (13.0)
Other 36 (0.4) 20 (0.6) 16 (0.4)
Unspecified 477 224 253
Melanoma subtype, n (%) <0.001
Superficial spreading 4067 (68.2) 2129 (70.6) 1938 (65.8)
Nodular 1527 (25.6) 686 (22.8) 841 (28.6)
Lentigo maligna 229 (3.8) 137 (4.6) 92 (3.2)
Acral 32 (0.6) 20 (0.6) 12 (0.4)
Other 106 (1.8) 42 (1.4) 64 (2.2)
Unspecified 2126 1038 1088
Breslow thickness (mm), median (range) 1 (0.1–70.0) 1 (0.1–65.0) 1.1 (0.1–70.0) <0.001
T-stage, n (%) <0.001
T1 (≤1.0 mm) 3745 (51.8) 2038 (56.0) 1707 (47.6)
T2 (1.01–2.0 mm) 1561 (21.6) 786 (21.6) 775 (21.6)
T3 (2.01–4.0 mm) 1112 (15.4) 469 (12.8) 643 (18.0)
T4 (>4.0 mm) 812 (11.2) 352 (9.6) 460 (12.8)
Unspecified 857 407 450
Clark level, n (%) <0.001
II 1484 (28.6) 825 (31.2) 659 (25.8)
III 1885 (36.2) 927 (35.2) 958 (37.4)
IV 1553 (29.8) 752 (28.4) 801 (31.4)
V 273 (5.2) 135 (5.2) 138 (5.4)
Unspecified 2892 1413 1479
Ulceration, n (%) <0.001
Present 1200 (27.0) 508 (23.0) 692 (30.8)
Not present 3249 (73.0) 1693 (77.0) 1556 (69.2)
Unspecified 3638 1851 1787
Clinical stage, n (%) <0.001
Local 6400 (91.8) 3280 (93.8) 3120 (89.8)
Regional metastasis 352 (5.0) 140 (4.0) 212 (6.2)
Distant metastasis 219 (3.2) 77 (2.2) 142 (4.0)
Unspecified 1116 555 561
Second primary CM, n (%) <0.001
0 7851 (97.0) 3963 (97.8) 3888 (96.4)
1 215 (2.6) 83 (2.0) 132 (3.2)
>1 21 (0.2) 6 (0.2) 15 (0.4)  
Note: *P-value from testing the difference between men and women.
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High mortality due to cutaneous melanoma in Norway
proportion was 47.6%. T-stage and Clark level were different 
for men and women. The proportion of Clark II tumors was 
31.2% in women and 25.8% in men (Table 1). Increasing 
T-stage with increasing age at diagnosis was seen for both 
sexes (Figure 1).
Presentation of ulceration was more frequent in men 
(30.8%) than in women (23%; Table 1). Moreover, the 
presence of ulceration increased by age (Figure 1) and with 
increasing T-stage; ulceration was present in 73.8% of the 
T4 tumors (data not shown).
In total, 91.8% of the cases were diagnosed in a local 
stage, whereas 5% had regional metastases and 3.2% had 
distant metastases (Table 1). Advanced clinical stage at 
diagnosis was more common in men than in women.
Median time of follow-up was 4.0 years (range 0.08–
7.5 years), and during follow-up, 1015 deaths occurred due 
to CM, representing 52.8% of all deaths (n=1921) and 78.7% 
of all deaths before the age of 50 years. Figure 2 shows the 
cumulative incidences of CM-specific death and death due to 
other causes (2008–2015). After 3 years, the estimated risk 
of dying from CM was 9.7%, the risk of dying from other 
causes was 7.8%, and the odds of being alive were 82.5%. 
The corresponding numbers after 5 years were 12.5%, 12.1%, 
and 75.5%, respectively. Cumulative incidence plots showed 
higher risk of CM-specific death in men than in women, 
as well as an increasing risk of death with increasing age, 
T-stage, and clinical stage (Figure 3). Low survival was 
observed for CMs with unspecified T-stage (Figure 3). The 
NM type comprised the dominant proportion of fatal CM 
cases (55.3% in women and 64.8% in men), and 70.2% of 
patients were in T-stage T3 or T4 (data not shown).
In total, 5010 cases had complete data for the anatomic 
site, melanoma subtype, Breslow thickness, ulceration, and 
clinical stage. The percentage distribution per variable, in 
total and stratified by sex, was quite similar in the simulated 
data (Table S1).
Sex, age, anatomic site, T-stage, ulceration, clinical stage, 
and having a second primary CM were associated with 
Figure 1 (A) Anatomic site, (B) melanoma subtype, (C) T-stage, and (D) ulceration in CM cases diagnosed in Norway in 2008–2012, according to sex and age (n=8087).
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CM-specific death, both in crude and multivariate analyses, 
whereas melanoma subtype was associated with CM-specific 
death in crude analysis only and not after adjustment for 
T-stage (Table 2). Complete-case analyses showed similar 
results (Table S2). The effect of sex was, however, slightly 
stronger in patients aged <70 years compared to those aged 
≥70 years of age (HRs [95% CIs] were 1.41 [1.15–1.74] and 
1.17 [0.95–1.45], respectively), but there was no interaction 
between age and sex.
Discussion
Our main findings are that male sex and advancing age are 
independent prognostic factors of CM-specific death and that 
higher T-stage, presence of ulceration, and advanced clinical 
stage are associated with male sex and high age, explaining 
the high mortality rate due to CM in Norwegian men. The 
dominant proportion of fatal CM cases was made up of the 
NM type. Analyses based on imputed missing data and the 
complete-case data gave similar results.
Few population-based CM registries with both clinical 
and histopathological data exist, and results from these 
registries cover different time periods and geographical 
Figure 2 Cumulative incidence of death due to CM and death from other causes 
in patients diagnosed in 2008–2012, based on the nonparametric method, taking 
competing events into account (n=8087).
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Figure 3 Cumulative incidence of death due to CM according to (A) sex, (B) age groups, (C) T-stage, and (D) clinical stage at diagnosis in patients diagnosed in 2008–2012 
(n=8087), based on the nonparametric method, taking competing events into account.
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High mortality due to cutaneous melanoma in Norway
areas.7,20–25 Although this may complicate comparisons, the 
present results are discussed based on data from comparable 
registries.
We found that median age at first CM diagnosis was 
64 years, and this is higher than that observed in Swedish 
(59.5 years, 1990–1999),20 Australian (54 years, 1986–1996), 
and Central European databases (54 years, 1986–1996),21 
but similar to that reported in the most recent Swedish data 
(64 years, 2007–2011).7 Our finding of increasing risk of 
CM-specific death by increasing age, even after adjustment 
for established prognostic factors, is in line with previous 
studies.20,26 Furthermore, we found a weaker effect of sex 
in CM patients ≥70 years of age, in line with Lasithiotakis 
et al,26 but contrary to the more recent study by Khosrotehrani 
et al,18 suggesting a survival benefit for patients >60 years of 
age (women only).
The anatomic site distribution of CM was in line with 
previous reports from Norway9,27 and Sweden,20 with the 
trunk as the main site (48.0%), although more prevalent in 
men (60.4%) than in women (35.8%). In agreement with 
other studies,28,29 trunk CM had a less favorable prognosis 
than CM at other anatomic sites, which may explain some 
of the difference in prognosis between the sexes.
SSM was, as expected, the dominant melanoma subtype. 
However, NM was more prevalent in Norway in the period 
2008–2012 (22.8% in women and 28.6% in males) than 
reported in previous studies: Sweden (21.0%, 1990–1999),20 
Surveillance, Epidemiology, and End Results (SEER) 
Table 2 HRs for CM-specific death, with 95% CIs, by sex, age, anatomic site, melanoma subtype, T-stage, ulceration, clinical stage, and 
having a second primary CM from crude and multivariate analyses (n=8087)
Characteristics CM-specific death, n Crude analysis Multivariate analysis
HR 95% CI HR 95% CI
Sex
Women 359 1.00 1.00
Men 616 1.83 1.60–2.08 1.29 1.11–1.50
Age (years)
<50 119 1.00 1.00
50–69 390 1.80 1.47–2.21 1.20 0.96–1.51
≥70 466 3.05 2.49–3.73 1.53 1.23–1.91
Anatomic site
Trunk 393 1.00 1.00
Head/neck 128 1.32 1.07–1.62 0.78 0.61–0.99
Arm 85 0.77 0.61–0.98 0.61 0.48–0.79
Leg 150 0.83 0.68–1.01 0.76 0.61–0.93
Other 12 4.33 2.35–7.98 1.07 0.50–2.26
Melanoma subtype
Superficial spreading 213 1.00 1.00
Nodular 301 4.30 3.54–5.22 1.01 0.79–1.29
Lentigo maligna 9 0.91 0.46–1.81 0.93 0.46–1.86
Other 21 3.91 2.21–6.93 0.67 0.40–1.14
T-stage
T1 (≤1.0 mm) 89 1.00 1.00
T2 (1.01–2.0 mm) 134 3.73 2.83–4.91 3.21 2.43–4.25
T3 (2.01–4.0 mm) 209 8.96 6.96–11.54 6.17 4.63–8.23
T4 (>4.0 mm) 257 21.73 17.14–27.55 9.68 7.06–13.28
Ulceration
Present 274 4.72 3.96–5.64 1.34 1.06–1.71
Not present 215 1.00 1.00
Clinical stage
Local 438 1.00 1.00
Regional metastasis 156 9.06 7.58–10.83 4.00 3.26–4.90
Distant metastasis 159 28.51 23.63–34.41 16.82 12.88–21.95
Second primary CM
0 940 1.00 1.00
1 30 1.43 0.99–2.05 2.67 1.79–3.99
>1 5 2.95 1.22–7.12 6.17 2.51–15.17
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 program of the National Cancer Institute (12.6%, 1989–
2009),25 and Queensland, Australia (15.2%, 1984–1996).21 
The median tumor thickness in Norway was 1.0 mm (1.1 mm 
in men), thicker than that reported in other registries.20,21,25 
Compared to other studies, we also found a higher proportion 
of cases with T4 tumors20,21,23–25 and fewer with T1.7,20,23,25 In 
the SEER22,25 and in Australia,23 the reported proportion of T1 
tumors was close to 70%, compared to 51.8% in the current 
study. Hence, thicker tumors with higher levels of infiltra-
tion may explain the higher mortality rate in Norway. In the 
first 3 years after diagnosis, the highest risk of CM-specific 
death was seen for cases with unspecified T-stage (Figure 3), 
and the HR for CM-specific death was at the same level as 
found for T3 (Table 2). This is in line with recent findings 
from the USA.30
Ulceration is a strong prognostic factor.3–5 The propor-
tion of missing data on ulceration in the current study was 
high, similar to that found in Swedish studies.20,31 In Norway, 
pathologists tend to report on ulceration only when it is 
present, not when it is absent. When collapsing the groups 
“unspecified” and “not present”, the proportion of ulceration 
was 14.8%, slightly lower than the proportion of ulceration 
found in Sweden (16.7%). Ulceration was more frequent in 
men, and the occurrence increased with age, further explain-
ing the higher mortality rates in old men.
Clinical stage at diagnosis has also been established as a 
strong prognostic factor.3–5 In our population, 91.6% of the 
patients were diagnosed with local disease in 2008–2012 
(92.8% including unspecified stage; Table 1), a lower propor-
tion than that reported from Sweden in 1990–1999 (95.3%)20 
and Central Europe in 1984–1996 (96.2%)21 and comparable 
to that in the SEER cohort in 1989–2009 (92.4%).25 Thus, 
Norwegian CM patients seem to be diagnosed in a more-
advanced disease stage, explaining the lower survival relative 
to CM patients in other registries. Local disease was also less 
common in men (89.6%) than in women (93.7%), contribut-
ing to higher mortality rates among men.
The high proportions of T3 and T4 tumors, as well as 
NM, among the fatal CM cases are of special interest. In 
data from SEER22 and Queensland, Australia,32 the propor-
tions of T1 tumors among CM patients with fatal outcome 
were 27% and 23%, respectively, ie, higher than that in the 
present study (12.1%). The NM/SSM ratio was 0.79 among 
the fatal CM cases in SEER in 1978–200733 and 1.45 in 
Victoria, Australia, in 1989–2004.34 In Sweden, conflicting 
ratios for fatal CM have been published for local disease: 
1.38 for 1990–199920 and 0.5 for 1989–2003.35 We found 
an NM/SSM ratio of 1.4 for fatal CM and 1.1 for CM with 
local disease at diagnosis. Hence, the proportion of NM 
compared to SSM, both in incident and fatal cases, seems to 
be high in Norway compared to most other population-based 
registries. In SEER, the contribution of NM to fatal CM 
(excluding unspecified) was reported to be stable between 
1978 and 2007 (37%) and SSM was the largest contributor 
to CM-specific death (46%).33 In our study and in the study 
from Victoria, Australia,34 NM was the main contributor to 
CM-specific death, 55% and 50%, respectively. Symmetri-
cal NM is more easily misdiagnosed compared to SSM,36 
and a low diagnostic sensitivity for NM compared to SSM 
is documented.37 Tumors of the NM type are escaping the 
established asymmetry, border, color, diameter, evolving 
(ABCD[E]) diagnostic guideline,38 which affects aware-
ness and thus prognosis. We found an association between 
melanoma subtype and CM-specific death in crude analysis 
only, in line with the literature, which states that the prog-
nostic significance of melanoma subtype is due to tumor 
thickness.4 CMs with high growth rate are associated with 
male sex, age >70 years, as well as symmetry and elevation 
of the lesion,39 which together with low awareness, may 
explain the high mortality rate in Norway.
Individuals with a history of CM are found to have an 
increased risk of a second CM diagnosis,40 and this may have 
an effect on survival in CM. We found that multiple primary 
CMs during the study period are a prognostic factor for CM-
specific death, in accordance with a study by Rowe et al.41
The main limitation of this study is the proportion of cases 
with missing clinical and histopathological data. We found 
that cases with unspecified data on T-stage had elevated risk 
of CM-specific death, indicating more advanced disease in 
these patients. Lack of information may result from incom-
plete diagnostic procedures in cases with thick tumors, 
distant metastases, or an unknown primary tumor. We had 
complete data on the anatomic site, melanoma subtype, 
Breslow thickness, ulceration, and clinical stage for 61.7% 
of the patients, a proportion in line with the Swedish data 
from 1990–1999 (65.1%).20 According to the Norwegian 
guidelines for diagnosis, treatment, and follow-up of CM in 
the period 2008–2015,14 no modifications have been done 
with regard to reporting and registration of clinical stage, 
Clark, subtype, or Breslow thickness during the study period. 
We used multiple imputation to impute missing data, and 
importantly, results from the Cox regression analyses of 
the prognostic factors were similar for the imputed and the 
complete-case data. Unfortunately, information on comorbid-
ity was not available. This may be of particular importance 
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patients. Information on education and ethnicity was not 
available. Educational level may influence sun exposure 
habits, health concerns, and doctor delay. Ethnicity may be 
of less relevance as Norway has a public health care system 
that aims to provide equal access to health care. Further-
more, except for breast cancer, no stage-based differences 
at diagnosis were observed between immigrant groups and 
Norwegians in a recent study.42
During the final part of the study period, immunotherapies 
and kinase inhibitors have been implemented in the treatment 
of advanced CM in Norway. Thus, future comparisons of sur-
vival and mortality data must take secular trends into account, 
as new treatments for distant metastases are emerging.
Conclusion
The high mortality rates among Norwegian CM patients 
may be explained by the more-advanced disease stage at 
diagnosis compared with the rates among CM patients in 
other countries. The high proportion of NM may contribute 
to high mortality rates, and the occurrence of more-advanced 
disease in men can explain the difference seen between the 
sexes. The results indicate an impact of patient delay because 
the highest incidence rates, the worst prognostic factors, 
and the highest risk of CM-specific death are found among 
older patients, especially among men; hence, efforts should 
be made to improve secondary prevention of CM in these 
patients. The clinical characteristics of NM must be com-
municated to both health care professionals and the public 
for increased awareness.
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Supplementary materials
Table S1 Distribution of the imputed variables
Characteristics Total Women Men
Anatomic site, n=477
Trunk 47.6 35.5 59.9
Head/neck 14.4 13.2 15.6
Arm 13.8 16.6 11.0
Leg 23.6 34.1 13.0
Other 0.6 0.6 0.6
Melanoma subtype, n=2126
Superficial spreading 66.1 68.6 63.6
Nodular 27.2 24.4 30.0
Lentigo maligna 3.9 4.7 3.2
Other 2.8 2.4 3.2
T-stage, n=857
T1 (≤1.0 mm) 50.2 54.6 45.8
T2 (1.01–2.0 mm) 21.2 21.2 21.2
T3 (2.01–4.0 mm) 15.7 13.2 18.2
T4 (>4.0 mm) 12.9 11.0 14.8
Ulceration, n=3638
Present 26.3 22.5 30.1
Not present 73.7 77.5 69.9
Clinical stage, n=1116
Local 91.1 93.1 89.1
Regional metastasis 5.4 4.2 6.6
Distant metastasis 3.5 2.6 4.4
Table S2 HRs for CM death, with 95% CIs, by sex, age, anatomic site, melanoma subtype, T-stage, ulceration, clinical stage, and 
presence of a second primary CM from crude and multivariate analyses of complete-case data (n=5010)
Characteristics CM-specific death, n Crude analysis Multivariate analysis
HR 95% CI HR 95% CI
Sex
Women 85 1.00 1.00
Men 164 2.00 1.54–2.60 1.33 1.00–1.76
Age (years)
<50 25 1.00 1.00
50–69 93 1.98 1.27–3.08 1.28 0.82–2.00
≥70 131 4.02 2.62–6.17 1.81 1.17–2.82
Anatomic site
Trunk 137 1.00 1.00
Head/neck 34 0.92 0.63–1.35 0.62 0.42–0.92
Arm 31 0.77 0.52–1.13 0.71 0.48–1.06
Leg 43 0.62 0.44–0.87 0.78 0.54–1.12
Other 4 0.73 0.27–1.98 0.79 0.29–2.15
Melanoma subtype
Superficial spreading 93 1.00 1.00
Nodular 145 4.50 3.47–5.84 0.91 0.66–1.25
Lentigo maligna 4 0.82 0.30–2.24 1.04 0.36–2.96
Other 7 2.53 1.17–5.45 0.52 0.23–1.17
T-stage
T1 (≤1.0 mm) 26 1.00 1.00
T2 (1.01–2.0 mm) 42 4.23 2.60–6.91 3.59 2.19–5.91
T3 (2.01–4.0 mm) 76 11.03 7.07–17.22 7.97 4.81–13.19
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Characteristics CM-specific death, n Crude analysis Multivariate analysis
HR 95% CI HR 95% CI
Ulceration
Present 105 4.94 3.84–6.36 1.37 1.04–1.82
Not present 144 1.00 1.00
Clinical stage
Local 153 1.00 1.00
Regional metastasis 71 12.26 9.25–16.27 5.39 3.97–7.32
Distant metastasis 25 40.24 26.27–61.64 19.32 12.40–30.08
Second primary CM
0 235 1.00 1.00
1 11 1.87 1.02–3.43 3.81 2.03–7.13
>1 3 3.65 1.16–11.47 7.71 2.38–24.98
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